The Cost-Effectiveness of Dabigatran and the Opportunity Cost of Delayed Subsidised Access in Australia
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1285
https://www.valueinhealthjournal.com/article/S1098-3015(13)03190-2/fulltext
Title :
The Cost-Effectiveness of Dabigatran and the Opportunity Cost of Delayed Subsidised Access in Australia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03190-2&doi=10.1016/j.jval.2013.08.1285
First page :
A526
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1129